Continuous Glucose Monitoring in Infants

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-2
SponsorUniversity of California, San Diego

About this trial

The purpose of this study is to employ continuous glucose monitoring to measure glucose profiles in newborn infants.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Mother at least 18 years of age

Infants born either appropriate for gestational age (AGA) or large for gestational age (LGA)

Skin fold over superior gluteus area at least 1 inch in thickness as measured by skin calipers

Disqualifiers

Infants born small for gestational age (SGA)

Infant birth weight <2.5 kg

Infant BMI <10th percentile on Olsen chart

Infants born <38 weeks gestation

Trial population

Mother/infant dyads will be admitted at UCSD Jacobs Medical Center for antepartum and postpartum care.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Dexcom continuous glucose monitor

    Device

    Measurement of interstitial glucose

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: No increased risk of hypoglycemia1 intervention
Group B: Increased risk of hypoglycemia1 intervention

Trial outcomes

Primary outcomes

1

Time spent with glucose <40 mg/dL

The Dexcom continuous glucose monitors measure interstitial fluid glucose values every 5 minutes. Data obtained from the Dexcom tracings will allow us to quantify how much time both infants with no risk for hypoglycemia (defined here as \<40 mg/dL) and those with risk factors for hypoglycemia spend at a blood glucose of \<40 mg/dL.

Time frame
The device will be worn from about 2 hours after birth until hospital discharge, up to a maximum of 10 days. It will be removed sooner if required for medical care or if the parent requests removal.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.